U.S. Markets close in 4 hrs 22 mins

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1060-0.0040 (-3.64%)
As of 10:33AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1100
Open0.1020
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0937 - 0.1100
52 Week Range0.0580 - 0.2034
Volume88,100
Avg. Volume607,906
Market Cap25.092M
Beta (5Y Monthly)-0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.0270
Earnings DateDec 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • GlobeNewswire

    Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capabilities

    FRAMINGHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that it has entered into a non-exclusive distribution agreement with Lovell Government Services (“LGS”), a Service-Disabled Veteran-Owned Small Business (“SDVOSB”), to support and drive sales through the Veteran’s Affairs hospitals and other governmental medical facilities. The

  • GlobeNewswire

    Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales

    Medical Industry Veteran with Proven Track Record to Drive Commercialization Effort FRAMINGHAM, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that Dan Yrigoyen has joined the organization as Vice President of Sales. Mr. Yrigoyen will lead the Company’s national commercialization effort with a focus on revenue generation and channel development. Mr. Yr

  • GlobeNewswire

    Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021

    FRAMINGHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will present at the upcoming Ladenburg Thalmann 2021 Healthcare Conference, which shall be held July 13-14, 2021. Chief Executive Officer, Terry Norchi, MD, is scheduled to provide a corporate update and, along with Chief Financial Officer, Mike Abrams, participate in a subsequent quest